Author

Ruji Yao 1

1 Merck Research Laboratories, North Wales, United State

CALPROTECTIN IS LESS ACCURATE THAN MAYO ENDOSCOPY SCORE TO MONITOR CONTINUOUS CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Walter Reinisch, Jean-Frederic Colombel, Ahmed Khalifa, Ruji Yao, Susan Huyck, George Philip, Freddy Cornillie

FIVE-YEAR SAFETY DATA FROM THE OBSERVATIONAL POSTMARKETING ULCERATIVE COLITIS STUDY, A EUROPEAN REGISTRY FOR ADULTS WITH ULCERATIVE COLITIS TREATED WITH ORIGINATOR INFLIXIMAB OR STANDARD THERAPY

Julian Panés, James Lindsay, Niels Teich, Stefan Lindgren, Jean-Frederic Colombel, Freddy Cornillie, Heather Ann Flynn, Susan Huyck, Paul Stryszak, Ruji Yao, George Philip, Walter Reinisch

HOW LONG SHOULD GOLIMUMAB TREATMENT BE CONTINUED IN PATIENTS WITH ULCERATIVE COLITIS WHO DO NOT RESPOND TO INITIAL INDUCTION THERAPY?

Paul Rutgeerts, Walter Reinisch, Brian G. Feagan, William Sandborn, Dino Tarabar, Zbigniew Hebzda, Ruji Yao, Colleen W. Marano, Richard S Strauss

LACK OF EARLY RESPONSE AND MUCOSAL HEALING IS ASSOCIATED WITH COLECTOMY IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS TREATED WITH GOLIMUMAB IN THE PURSUIT-M TRIAL

Jean-Frederic Colombel, Colleen W. Marano, George Philip, Susan Huyck, Ruji Yao, Freddy Cornillie

RELATIONSHIP BETWEEN CLINICAL OUTCOMES AND DISEASE DURATION, EXTENT, AND SEVERITY IN PATIENTS WITH ULCERATIVE COLITIS WHO RECEIVED 6 WEEKS OF TREATMENT WITH GOLIMUMAB

William Sandborn, Brian G. Feagan, Jean-Frederic Colombel, Walter Reinisch, Peter R. Gibson, Paul Rutgeerts, Ruji Yao, Colleen W. Marano, Richard S Strauss

WEIGHT-BASED MAINTENANCE DOSING OF GOLIMUMAB IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Paul Rutgeerts, Walter Reinisch, Brian G. Feagan, William Sandborn, Dino Tarabar, Zbigniew Habzda, Ruji Yao, Colleen W. Marano, Richard S Strauss

Item 1 - 6 / 6
1